Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pretreated Multiple Myeloma: Old/New in NOVEL Agents' Era

被引：2
|
作者：
Cerchione, Claudio
Catalano, Lucio
Nappi, Davide
Rocco, Stefano
Palmieri, Salvatore
Pareto, Anna Emanuele
Musuraca, Gerardo
Lucchesi, Alessandro
Pane, Fabrizio
Ferrara, Felicetto
Martinelli, Giovanni
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-143207
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Chemo or Chemo-Free Regimens in Heavily Pretreated Multiple Myeloma? Role of Bendamustine-BortezomibDexamethasone (BVD) in Novel Agents' Era
    Nappi, Davide
    Catalano, Lucio
    Pareto, Anna Emanuele
    Musuraca, Gerardo
    Ronconi, Sonia
    Ceccolini, Michela
    Cangini, Delia
    Pane, Fabrizio
    Martinelli, Giovanni
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S426 - S426
  • [22] ROLE OF BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REAL-LIFE EXPERIENCE
    Cerchione, C.
    Catalano, L.
    Pareto, A. E.
    Basile, S.
    Marano, L.
    Peluso, I.
    Simeone, L.
    Vitagliano, O.
    Palmieri, S.
    Rocco, S.
    Ferrara, F.
    Pane, F.
    HAEMATOLOGICA, 2016, 101 : S82 - S82
  • [23] Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
    Cerchione, Claudio
    Nappi, Davide
    Di Perna, Maria
    Zacheo, Irene
    Pareto, Anna Emanuele
    Picardi, Marco
    Catalano, Lucio
    Pane, Fabrizio
    CASE REPORTS IN HEMATOLOGY, 2016, 2016
  • [24] Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma
    Mele, Giuseppe
    Spina, Alessandro
    Guaragna, Gianluca
    Giannotta, Angela
    Melpignano, Angela
    Quarta, Gianni
    LEUKEMIA & LYMPHOMA, 2014, 55 (05) : 1191 - 1193
  • [25] Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series
    Magen, Hila
    Geva, Mika
    Volchik, Yulia
    Avigdor, Abraham
    Nagler, Arnon
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (12): : E947 - E955
  • [26] Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone
    Cerchione, Claudio
    Catalano, Lucio
    Peluso, Ilaria
    Nappi, Davide
    Di Perna, Maria
    Salvatore, Dalila
    Migliaccio, Ilaria
    Picardi, Marco
    Pane, Fabrizio
    SUPPORTIVE CARE IN CANCER, 2016, 24 (12) : 4835 - 4837
  • [27] MANAGING NEUTROPENIA BY PEGFILGRASTIM IN PATIENTS AFFECTED BY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE
    Cerchione, C.
    Catalano, L.
    Peluso, I.
    Nappi, D.
    Di Perna, M.
    Picardi, M.
    Pane, F.
    HAEMATOLOGICA, 2016, 101 : S118 - S118
  • [28] Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma
    Ludwig, Heinz
    Kasparu, Hedwig
    Leitgeb, Clemens
    Rauch, Elisabeth
    Linkesch, Werner
    Zojer, Niklas
    Greil, Richard
    Seebacher, Adelheid
    Pour, Ludek
    Weissmann, Adalbert
    Adam, Zdenek
    BLOOD, 2014, 123 (07) : 985 - 991
  • [29] Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone
    Claudio Cerchione
    Lucio Catalano
    Ilaria Peluso
    Davide Nappi
    Maria Di Perna
    Dalila Salvatore
    Ilaria Migliaccio
    Marco Picardi
    Fabrizio Pane
    Supportive Care in Cancer, 2016, 24 : 4835 - 4837
  • [30] Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma
    Jimenez-Zepeda, Victor H.
    Reece, Donna E.
    Trudel, Suzanne
    Chen, Christine
    Tiedemann, Rodger
    Kukreti, Vishal
    LEUKEMIA & LYMPHOMA, 2013, 54 (03) : 555 - 560
12345